Pegylated thymalfasin

Drug Profile

Pegylated thymalfasin

Alternative Names: Pegylated Zadaxin

Latest Information Update: 27 Mar 2009

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Nektar Therapeutics; SciClone Pharmaceuticals
  • Class Adjuvants; Antineoplastics; Antivirals; Oligopeptides; Thymus hormones
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Cancer; Hepatitis B; Hepatitis C

Most Recent Events

  • 02 Jun 2004 Preclinical trials in Cancer in USA (Parenteral)
  • 02 Jun 2004 Preclinical trials in Hepatitis B in USA (Parenteral)
  • 02 Jun 2004 Preclinical trials in Hepatitis C in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top